| | Latest News | Catalent Completes Commercial-Scale Plasmid DNA Manufacturing Facility in Gosselies, Belgium |
|
| Catalent announced the opening of a new commercial-scale plasmid DNA (pDNA) manufacturing facility at its European center of excellence for cell therapies, in Gosselies, Belgium. The state-of-the-art facility contains over 12,000 square feet (1,100 square meters) of development and manufacturing space, across multiple cleanrooms, for the dedicated production of CGMP-grade pDNA for clinical- and commercial-phase supply. |
|
| | Read the article | Catalent Launches New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies |
|
| Catalent launched a new Case Management Service, which has been specifically designed to address the unique challenges associated with the safe and timely delivery of advanced therapies to patients by providing professional supply chain oversight from program start to finish. |
|
| | Read the article | Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader |
|
| Welcoming Mr. Zayas to Catalent, Alessandro Maselli, President & Chief Executive Officer, commented, “Ricardo brings vast senior management experience to Catalent’s leadership team, which he will draw upon as we execute the next stage of our strategic growth plans in biologics that we have been implementing over the past few years. We have made significant investments |
|
| in facilities, assets, and new technologies across North America, and Ricardo will be working closely with the team we have in place to meet the demands of our customers’ therapies and medicines, enhancing operational excellence, and bringing a growing pipeline of innovative treatments to patients.” | | Read the article | Catalent in the News | TASCENSO ODT® (fingolimod), launched to support the needs of multiple sclerosis patients |
|
| John Reid, Patient Support Director of Cycle Pharmaceuticals Ltd commented, “The launch of TASCENSO ODT comes at a critical time for patients already on Gilenya or generic fingolimod therapy. |
|
| TASCENSO ODT is the first orally disintegrating tablet, or ODT, approved to treat MS patients in the US. Its unique ODT formulation was developed by our partner Catalent using its best-in-class ZYDIS technology which dissolves on the tongue in seconds, without the need for water. We expect this ODT formulation to be an attractive option for MS patients looking for convenience, and testament to that, we are already receiving TASCENSO ODT enrolment forms.” | | Read more |
|
| Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement |
|
| Avantor® announced that it has entered into a multi-year supply and services agreement with Catalent. "Catalent has built tremendous global capabilities and a reputation as a trusted collaborator to pharma, biotech and consumer health partners throughout the development and production lifecycle," said Michael Stubblefield, President and CEO of Avantor. |
|
| | | Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA® |
|
| Acorda Therapeutics entered into a new long-term global supply agreement with Catalent for the manufacture of INBRIJA (levodopa inhalation powder) at its Center of Excellence for Spray Dried Dispersions in Boston where Catalent will continue to manufacture INBRIJA through to 2030. |
|
| “This agreement ensures that people with Parkinson’s who benefit from INBRIJA will have an uninterrupted supply of this important medication, and that it continues to be manufactured to the highest quality and safety standards,” said Ron Cohen, M.D., Acorda’s President and Chief Executive Officer. | | Read more | SPECIAL FEATURE – Outsourcing Analytical Testing – Timelines, Regulations & Biologics Drive the Sector |
|
| | | “The company strives to ensure ‘right-first-time’ results, streamlined workflows, and flexible resourcing to meet evolving client demands,” commented Emily Magner-Fink, Director, Commercial Operations, Catalent Bioanalytical Services. | | Read more | Next-generation ADCs: better oncology treatments through innovation |
|
| In European Pharmaceutical Manufacturer, Penelope Drake, Ph.D., Head of R&D, Bioconjugates, Catalent, highlights the potential of antibody-drug conjugates (ADCs) in paving a way to innovation in oncology treatments. |
|
| | | Catalent for Building Better Biotechs |
|
| Article: A Q&A with Jim Spavins In nearly 40 years at Pfizer and as a consultant, Jim Spavins has helped many scientists make the jump from purely academic approaches to meet the needs of the boardroom too. We sat down with Jim, a board member of the Catalent Applied Drug Delivery Institute, to discuss what founders must consider when launching a biotech start-up, how to navigate complex regulatory and funding challenges, and the benefits of partnering with trusted CDMOs. |
|
| | | Upcoming Events: Join Our Experts to Hear the Latest on Technology Development Programs and Commercial Programs |
|
| DCAT Week 2023 | New York City | March 20-23, 2023 The Catalent team is excited to be back in New York City for #DCATWeek this March. Schedule a meeting today with our experts and learn how we can help with your next project. Schedule a meeting |
Biologics
CAR-TCR Summit Europe | London, UK | February 21-23, 2023
Meet with Catalent cell & gene therapy experts in booth #10 and learn about strategies for commercial scalability for manufacturing of late-stage cell therapies and more in a dynamic session from Catalent General Manager, Cell and Gene Therapy, Luca Russo, titled “Strategic Considerations for Scaling Up the Manufacturing of Cell Therapies” on February 22. Schedule a meeting
World ADC London 2023 | London, UK | March 13-16, 2023 Join Stepan Chuprakov, Ph.D., as he presents new data highlighting the improved efficacy and tolerability of Catalent’s unique SMARTag® ADC technology as compared to marketed ADCs against the same targets. Schedule a meeting
BEBPA 2023 US Bioassay Conference | Seattle, Washington State | March 14-16 Join our Catalent Biologics experts and stop by our booth to learn more about our biologics and large molecule analytical services, and new technologies and techniques that can be employed on new modalities. Schedule a meeting
BIO Europe Spring 2023 | Basel, Switzerland | March 20-22, 2023
Catalent is a proud sponsor at this year’s Bio-Europe Spring, the largest gathering of biopharma professionals in the industry. Take the opportunity to network and schedule time with our team at booth 32, and learn how we can simplify and de-risk your biologic, from development through to clinical and commercial supply, faster. Schedule a meeting
Accelerating Biologics Through the Clinic: A Seamless Development-to-Manufacture Approach | Copenhagen, Denmark | March 28, 2023 Join us for this in-person event as industry experts focus on key considerations for transitioning a molecule from clinical to commercial scale, beginning with cell line development and biomanufacturing, to formulation and filling and managing clinical trial supply. Register now
Webinar | Development of Orphan Biologics: Challenges and Opportunities | April 18, 2023 The development of therapies for rare diseases comes with distinct challenges such as patient recruitment, and difficulties in setting meaningful clinical endpoints, as well as manufacturing and supply challenges. In this webinar, speakers will cover aspects of clinical trial design for orphan biologic products as well as key strategies for ensuring appropriate clinical trial supply throughout clinical development. Register now |
|
| Pharmaceuticals and Consumer Health
Webinar | Tackling Bioavailability Challenges for the Next Generation of Small Molecules | February 16, 2023 Join this webinar to hear industry experts share insights into small molecule drug development advancements and discuss innovative, scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability. Register now
Clinical Outsourcing Group UK | London, UK | February 21-22, 2023 Meet with Catalent experts at Booth #21 and hear from Stephanie Graham, Global Director, Clinical Supply Management, Catalent, about the strategies to build understanding of the protocol requirements, drug characteristics, packaging specifications and delve into ways to identify and mitigate risk within your clinical supply plan. Schedule a meeting
Alzheimer’s & Parkinson’s Drug Development Summit | San Francisco | February 21-23, 2023 Schedule a meeting with our experts in San Francisco and learn how Zydis ODT technology can offer patient-centric drug delivery for a wide range of neurological disorders.
BSMA Summit 2023 | Foster City, Calif. | March 8-9, 2023 Hear Matt Blume, VP, Business Transformation & Regional General Manager moderate the panel session, “The Industry Platform to Integrate Drug Developers with CRO, CMO, AND CDMO” on March 8. Visit the Catalent booth to discover how we can help you overcome your most pressing clinical development & supply challenges.
Schedule a meeting
Interphex Week Osaka 2023 | Osaka, Japan | March 8-10, 2023
Plan to visit our experts at Booth 12-22 to discover the innovative and flexible clinical supply solutions available from our Shiga facility in Japan, and across the globe. Register for our complimentary networking reception happening on March 9.
Schedule a meeting
CTS Europe 2023 | Milan, Italy | March 15-16, 2023 Visit Catalent at booth 11 to learn more from our clinical supply experts about our extensive world-leading capabilities in Europe and beyond! Schedule a meeting
Targeted Protein Degradation Summit Europe |London, UK | March 28-30, 2023 Join Steven Winling, Scientific Advisor, Science & Technology, as he discusses Catalent’s tailored developability assessment for bifunctional protein degraders, which can help predict viable formulation and drug delivery strategies for lead drug candidates to reach their true potential. Schedule a meeting
in-cosmetics Global 2023 | Barcelona, Spain | March 28-30, 2023 Meet the Catalent Beauty team at Booth N61 to learn more about our capabilities for your beauty needs and how we can partner with you on your next project. Schedule a meeting
Nicholas Hall’s 33rd CHC European Conference | London, UK | April 20-21, 2023 Visit our booth and meet Catalent’s experts to learn more about our development and manufacturing capabilities for consumer health products. Schedule a meeting
|
|
|
|
A Catalyst in Drug Development |
|
| Todd Stone, Ph.D. Director, Analytical Development |
|
| Dr. Stone is Director, Analytical Development at Catalent’s Bloomington, Indiana, facility. He and his team focus on developing statistically rigorous analytical methods and high throughput formulation strategies using the principles of Quality by Design (QbD). Dr. Stone leads the scientific direction of the analytical and formulation groups ensuring Catalent provides clients with the highest quality data characterizing the critical quality attributes of their molecules. View his Featured works |
|
| | |
|
Biologics Webinar: “Overcoming Manufacturing Challenges for Gene-Enabled Cell Therapies” Cell and gene therapies constitute a dynamic market with unprecedented growth. Join this webinar to as experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.
Webinar: “Strategic Considerations for Scaling Up the Manufacturing of Cell Therapies” Autologous and allogeneic therapies are at different stages of their product lifecycles, each with specific requirements for manufacturing that need to be accommodated. In this webinar, we explore the key considerations when scaling late-stage cell therapies and how Catalent’s new commercial scale facilities and customer-centric approach can help get therapies to patients faster.
Webinar: “Choose Your Partner Wisely-Lessons Learned to Accelerate Product Development” Listen in as experts share how new modalities and manufacturing technologies have altered the partnership landscape between developers and CDMOs. They also discuss common pitfalls that disrupt development timelines and how to successfully navigate the path to clinic while transforming breakthrough scientific ideas into real treatments for patients.
|
|
| Pharmaceuticals and Consumer Health |
|
| | | | | In this 360° virtual tour of our Anagni, Italy, site, explore the world-class late-stage and commercial manufacturing for vial fill/finish and secondary packaging of biologics and sterile products.
|
|
| Pharmaceuticals and Consumer Health
| In this 360° virtual tour , explore Catalent’s Beinheim, France, facility which houses Rx and OTC softgel development and manufacturing operations. This site specializes in formulation development and manufacturing solutions of controlled substances, highly potent compounds, and hormones.
|
|
| We are the Catalyst for your success. Join us! |
|
| Catalent ignites the development of their future leaders by continuously investing in their employees and creating an innovative environment to advance their potential. We are hiring across sites in North America, Latin America, Europe and Asia Pacific.
Visit www.catalent.com/careers for more information. |
|
| | |
|
Every molecule has a challenge. We have a solution.
|
|
| | | or call +1 877 891 9609 to speak with one of our experts today! |
|
| | |
|
To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers.
Catalent Pharma Solutions respects your privacy.
Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content.
© 2023, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved.
|
|
|
|
|
